Evidence map›Paper›PMID 34556300›Full record

GuidelineKidney international2021

Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.

Brad H Rovin, Sharon G Adler, Jonathan Barratt, Frank Bridoux, Kelly A Burdge, Tak Mao Chan, H Terence Cook, Fernando C Fervenza, Keisha L Gibson, Richard J Glassock and 25 more

Registry-linked trialAbstract readPractice Guideline
PubMed Publisher
In one paragraph

Guideline in Kidney international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07497776 (Atorvastatin Therapy in the Treatment of Dyslipidemia in Children With Steroid Sensitive Nephrotic Syndrome), which is not on this map. Cited by 476 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
476citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07497776 phase4completedstarted 2024, after this paper: background citation

Atorvastatin Therapy in the Treatment of Dyslipidemia in Children With Steroid Sensitive Nephrotic Syndrome

Ran2024Enrolled100Registered outcomes1Posted comparisons0ConditionsDyslipidaemiaArmsAtorvastatin
PMID 31302760PMID 30091061PMID 36494853PMID 40254391PMID 38319465PMID 36269406PMID 31830725PMID 31220048PMID 27165836other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

476 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

416 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Brad H RovinDepartment of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USA. Electronic address: brad.rovin@osumc.edu.
Sharon G AdlerDivision of Nephrology and Hypertension, Los Angeles Biomedical Research Institute, Los Angeles, California, USA.
Jonathan BarrattDepartment of Cardiovascular Sciences, University of Leicester, Leicester, UK.
Frank BridouxDepartment of Nephrology and Renal Transplantation, CIC INSERM 1402, Centre Hospitalier Universitaire, University Hospital Poitiers, Poitiers, France.
Kelly A BurdgeDivision of Nephrology, Mass General Brigham-Salem Hospital, Salem, Massachusetts, USA.
Tak Mao ChanDivision of Nephrology, Department of Medicine, University of Hong Kong, Hong Kong, China.
H Terence CookRenal and Transplant Centre, Imperial College London, London, UK.
Fernando C FervenzaDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Keisha L GibsonUniversity of North Carolina Kidney Center at Chapel Hill, Chapel Hill, North Carolina, USA.
Richard J GlassockDepartment of Medicine, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
David R W JayneDivision of Experimental Medicine & Immunotherapeutics, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Vivekanand JhaThe George Institute for Global Health, New Delhi, India; School of Public Health, Imperial College London, London, UK; Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India.
Adrian LiewThe Kidney and Transplant Practice, Mount Elizabeth Novena Hospital, Singapore.
Zhi-Hong LiuNanjing University School of Medicine, Nanjing, China.
Juan M Mejía-ViletDepartment of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Medicas y Nutricion, Salvador Zubiran, Mexico City, Mexico.
Carla M NesterMolecular Otolaryngology & Renal Research Laboratories, University of Iowa, Iowa City, Iowa, USA.
Jai RadhakrishnanDivision of Nephrology, Department of Medicine, Columbia University Medical Center, New York, New York, USA.
Elizabeth M RaveOhio Kidney Associates, Columbus, Ohio, USA.
Heather N ReichDivsion of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Pierre RoncoSorbonne University, and Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S1155, Paris, France; Le Mans Hospital, Le Mans, France.
Jan-Stephan F SandersDivision of Nephrology, Department of Internal Medicine, University of Groningen, Groningen, The Netherlands.
Sanjeev SethiDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Yusuke SuzukiDepartment of Nephrology, Juntendo University, Tokyo, Japan.
Sydney C W TangDivision of Nephrology, Department of Medicine, University of Hong Kong, Hong Kong, China.
Vladimír TesarDepartment of Nephrology, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
Marina VivarelliDepartment of Pediatric Subspecialties, Division of Nephrology and Dialysis, Ospedale Pediatrico Bambino Gesù, Rome, Italy.
Jack F M WetzelsDepartment of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands.
Lyubov LytvynMAGIC Evidence Ecosystem Foundation, Hamilton, Ontario, Canada; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
Jonathan C CraigCollege of Medicine and Public Health, Flinders University, Adelaide, Australia; Cochrane Kidney and Transplant, Sydney, New South Wales, Australia.
David J TunnicliffeCochrane Kidney and Transplant, Sydney, New South Wales, Australia; Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
Martin HowellCochrane Kidney and Transplant, Sydney, New South Wales, Australia; Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
Marcello A TonelliDepartment of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Michael CheungKDIGO, Brussels, Belgium.
Amy EarleyKDIGO, Brussels, Belgium.
Jürgen FloegeDivision of Nephrology, University Hospital, Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen, Aachen, Germany. Electronic address: jfloege@ukaachen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases is an update to the KDIGO 2012 guideline. The aim is to assist clinicians caring for individuals with glomerulonephritis (GN), both adults and children. The scope includes various glomerular diseases, including IgA nephropathy and IgA vasculitis, membranous nephropathy, nephrotic syndrome, minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), infection-related GN, antineutrophil cytoplasmic antibody (ANCA) vasculitis, lupus nephritis, and anti-glomerular basement membrane antibody GN. In addition, this guideline will be the first to address the subtype of complement-mediated diseases. Each chapter follows the same format providing guidance related to diagnosis, prognosis, treatment, and special situations. The goal of the guideline is to generate a useful resource for clinicians and patients by providing actionable recommendations based on evidence syntheses, with useful infographics incorporating views from experts in the field. Another aim is to propose research recommendations for areas where there are gaps in knowledge. The guideline targets a broad global audience of clinicians treating GN while being mindful of implications for policy and cost. Development of this guideline update followed an explicit process whereby treatment approaches and guideline recommendations are based on systematic reviews of relevant studies, and appraisal of the quality of the evidence and the strength of recommendations followed the "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) approach. Limitations of the evidence are discussed, with areas of future research also presented.

Indexed as

GlomerulonephritisGlomerulonephritis, IGAGlomerulonephritis, MembranousNephrosis, LipoidAdultChildHumansKidneyAAVANCAanti-GBMC3complementevidence-basedFSGSglomerular diseasesglomerulonephritisguidelineIgA nephropathyIgA vasculitisinfection-related glomerulonephritisKDIGOlupus nephritismembranous nephropathyminimal change diseaseMPGNnephrotic syndromesystematic review

Identifiers

PMID34556300

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.